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Abstract
Background: Refugees and host nationals who accessed antiretroviral therapy (ART) in a remote refugee camp in
Kakuma, Kenya (2011–2013) were compared on outcome measures that included viral suppression and adherence to ART.
Methods: This study used a repeated cross-sectional design (Round One and Round Two). All adults (≥18 years) receiving
care from the refugee camp clinic and taking antiretroviral therapy (ART) for ≥30 days were invited to participate.
Adherence was measured by self-report and monthly pharmacy refills. Whole blood was measured on dried blood
spots. HIV-1 RNA was quantified and treatment failures were submitted for drug resistance testing. A remedial
intervention was implemented in response to baseline testing. The primary outcome was viral load <5000 copies/mL.
The two study rounds took place in 2011-2013.
Results: Among eligible adults, 86% (73/85) of refugees and 84% (86/102) of Kenyan host nationals participated
in the Round One survey; 60% (44/73) and 58% (50/86) of Round One participants were recruited for Round Two
follow-up viral load testing. In Round One, refugees were older than host nationals (median age 36 years, interquartile
range, IQR 31, 41 vs 32 years, IQR 27, 38); the groups had similar time on ART (median 147 weeks, IQR 38, 64 vs
139 weeks, IQR 39, 225). There was weak evidence for a difference in the proportion of refugees and host nationals
who were virologically suppressed (<5000 copies/mL) after 25 weeks on ART (58% vs 43%, p = 0.10) and no
difference in the proportions suppressed at Round Two (74% vs 70%, p = 0.66). Mean adherence within each group in
Round One was similar. Refugee status was not associated with viral suppression in multivariable analysis (adjusted
odds ratio: 1.69, 95% CI 0.79, 3.57; p = 0.17). Among those not suppressed at either timepoint, 69% (9/13)
exhibited resistance mutations.
Conclusions: Virologic outcomes among refugees and host nationals were similar but unacceptably low. Slight
improvements were observed after a remedial intervention. Virologic monitoring was important for identifying an
underperforming ART program in a remote facility that serves refugees alongside host nationals. This work highlights
the importance of careful laboratory monitoring of vulnerable populations accessing ART in remote settings.
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Background
Life-long antiretroviral therapy (ART) that requires con-
sistent access to medications and supportive services is a
challenge in conflict-affected settings. By the end of 2013,
172 million people were affected by violent conflict world-
wide, while 51.2 million people were forcibly displaced as
a result of conflict, persecution, generalized violence, and
human rights violations [1, 2]. Of these, 16.7 million were
classified as refugees who had crossed an international
border to escape a well-founded fear of persecution in the
absence of protection in their home country. International
humanitarian and refugee law suggest that refugees should
receive an equivalent standard of medical care to host na-
tionals in countries where they have sought protection [3].
In many settings, refugees and host nationals receive HIV
services from the same facilities. An equivalent standard
of HIV care should result in similar treatment outcomes.
Few studies, however, have sought to rigorously compare
HIV treatment outcomes between refugee and host na-
tional groups. Previous work has shown high levels of ad-
herence to ART, increases in CD4 counts, and increases in
survival among confict-affected populations [4, 5]. In a
study comparing urban refugees situated in Kuala Lumpur
with Malaysian host nationals, we found comparable levels
of viral suppression [6]. Refugees, however, live in a variety
of settings (e.g., camps, cities, etc.), and it is not known
how these different environments might influence their
HIV treatment outcomes [7]. Better data will help govern-
ments and humanitarian agencies improve ART delivery,
while retaining more people along the HIV cascade of care
[8]. We report on a repeated cross-sectional study of ad-
herence and viral suppression among refugees and host
nationals accessing ART in Kakuma Refugee Camp,
Kenya, pre- and post- a remedial intervention that
responded to poor baseline levels of viral suppression.
Our aim was to compare viral suppression and adherence
to ART among refugees and host nationals and to identify
factors associated with viral suppression.
Methods
Study setting
Kakuma Refugee Camp is situated in a remote part of
Northwestern Kenya. In 2011, the camp's Comprehen-
sive Care Clinic was managed by the International Rescue
Committee (IRC) and was overseen by the United Nations
High Commissioner for Refugees (UNHCR). At study ini-
tiation (February 2011), the camp population was 82,409
(Somalia, 54%; Sudan, 32%; Ethiopia, 8%; Democratic Re-
public of the Congo, 5%). Local host nationals were pri-
marily Turkana, a nomadic-pastoralist group. Adult HIV
prevalence within the camp was 1.2% [9]. Clients who
tested positive for HIV were counseled and started on
multivitamins and cotrimoxazole, followed by ART at
CD4 < 250 cells/ul. After six months on ART, clinic
appointments were scheduled every six months; however,
clients typically presented at the clinic pharmacy on a
monthly basis to refill their ART prescriptions. At this
time, they could request a counseling session with a nurse
or community support worker. First-line regimens con-
sisted of two nucleoside reverse transcriptase inhibitors
(NRTIs), usually lamivudine with zidovudine, stavudine
or tenofovir, combined with a non-nucleoside reverse
transcriptase inhibitor (NNRTI) such as nevirapine or
efavirenz, given twice daily. Six months prior to the
study, stavudine was phased out as per 2009 World
Health Organization (WHO) recommendations. Routine
CD4-testing, counseling services, and nutritional supple-
mentation including additional rations of cornmeal and
peanut-based nutritional spread were provided to ART
clients.
Study design
This study used a repeated cross-sectional design with
baseline (Round One) and follow-up (Round Two) seg-
ments. We initially designed the baseline cross-
sectional survey. Round Two was initiated on the basis
of Round One results.
Round One
A five-week cross-sectional survey was implemented
between February and April 2011. All adults were in-
vited to participate if they accessed their treatment from
the Comprehensive Care Clinic, were ≥18 years old, had
been taking ART for ≥30 days, had not missed ≥6 con-
secutive monthly pharmacy refills, and were not exclu-
sively on ART for prevention of mother-to-child
transmission. Recruitment occurred during regular clinic
appointments or through an active recruitment protocol
implemented by community health workers. Three
attempts were made to contact all eligible adults by
telephone or home visit.
Round Two
In response to very low proportions of participants who
were virally suppressed in Round One, a remedial inter-
vention was implemented by IRC in December 2011 that
aimed to improve elements of the ART program. Inter-
vention measures included hiring an additional clinical of-
ficer and a full-time adherence support counselor,
construction of an additional adherence counseling room,
pill counting during appointments, closer monitoring of
the ART surveillance database, increased frequency of
CD4 monitoring (once per year increased to twice per
year), additional training for peer support counselors,
additional adherence counseling during appointments,
and intensified monitoring of clients with viral loads
≥5000 copies/mL. Baseline participants were re-contacted
between September 2012 and June 2013 and invited to
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provide a Round Two follow-up viral load. Survey ques-
tionnaires were not completed in Round Two. Follow-
ing Kenyan national guidelines, clients with a second
consecutive viral load of ≥5000 copies/mL were
switched to second-line ART.
Data sources and measures
A structured questionnaire was administered during
Round One. Data was collected on a pen and paper sur-
vey administered in a face-to-face interview conducted
in the respondent’s language of choice (usually the
mother tongue). Prior to pre-testing, the questionnaire
was translated from English into Swahili, Nga’turkana,
Somali, French and Juba Arabic, and back-translated
into English by an independent translator. Both versions
were then reconciled. HIV RNA-1 concentrations were
measured using dried blood spots collected on What-
man 903 filter paper and stored at -20 °C in the refugee
camp pharmacy storage facility. Samples were shipped
on dry ice to collaborating Kenya Medical Research In-
stitute (KEMRI) laboratories. Self-reported adherence
was measured using a 4-day dose-by-dose recall and a
one-month recall visual analogue scale where partici-
pants were asked to mark an “X” representing the
amount of medication they had taken during the previ-
ous month at any point along a 10 cm line [10, 11]. Ad-
herence to pharmacy prescription refill schedule was
estimated from pharmacy records as the proportion of
refills collected divided by the total number of refills
prescribed in the 24 months prior to the baseline inter-
view or since the month of ART initiation, whichever
was longer. The primary outcome was viral load <5000
copies/mL, consistent with WHO recommendations on
minimum cut-offs for viral loads measured from dried
spots [12].
Laboratory procedures
Viral loads were analyzed on the COBAS Ampliprep/
Taqman platform (Roche Diagnostics Systems,
Branchburg, New Jersey, USA). Round One samples
from clients with two consecutive viral loads ≥5000
copies/mL were submitted for drug resistance testing.
Sequencing was performed using a WHO-accredited
in-house genotyping assay. Sequenced samples were
analyzed on an ABI Prism 3130xl Genetic Analyzer
(Applied Biosystems, Foster City, CA, USA) and edi-
ted using RECall v2.0 Software, using HIV-1 HXB2
as the reference sequence [13]. Protease (PR) and re-
verse transcriptase (RT) fragments were confirmed
against the Stanford University HIV Drug Resistance
Database Version 7.0 ( http://hivdb.stanford.edu/) and
the International AIDS Society Mutation List [14, 15].
Statistical methods
Medians, proportions and corresponding 95% confi-
dence intervals (95% CI) were used to compare out-
comes. Risk factors were evaluated using unconditional
logistic regression. Effect estimates included odds ratios
(OR) and corresponding 95% CIs. A three-level hier-
archical, step-wise modelling approach was used to
order the entry of factors in multivariable models. Social
action theory, which emphasizes the influence of social
interaction and environmental structures on problem-
solving activities affecting health behaviors [16], was se-
lected as the conceptual framework given its consider-
ation of socio-structural factors relevant for refugee
camp settings. Drawing on social action theory, factors
were grouped into levels representing “treatment con-
texts” i.e., socio-demographic factors; “self-change fac-
tors” i.e., knowledge measures; and “action state factors”
i.e., adherence measures (see Additional files 1, 2 and 3).
Associations with viral suppression were evaluated in
univariable analyses using log-likelihood ratio tests. The
“treatment context model” was fitted by adjusting for
factors with p < 0.2 in univariable analyses. The “self-
change model” was fitted by adjusting for all retained
factors from the prior level, then adjusting again for any
additional self-change factors meeting the p < 0.2
threshold. Given detected collinearities, the “action
state model” was adjusted by factors from previous
model levels, but not by additional factors within this
level. The final multivariable model sequentially ex-
cluded factors with the highest p-values, until all fac-
tors met a p < 0.05 cut-off. Refugee status, age, and
time on ART were retained throughout modelling as
a priori covariates of interest. Given that adjustment
by mediating factors can introduce over-adjustment
bias, adherence factors were not included in the final
model [17].
Results
Study population
Among eligible HIV-positive clients who were enrolled
in the ART program, 86% (73/85) of refugees and 84%
(86/102) of Kenyan host nationals participated in Round
One. Among refugees, 11% (9/85) declined and 4%
(3/85) were not found; among host nationals 6% (6/102)
declined and 10% (10/102) were not found (Fig. 1). Viral
loads were collected from 159 clients during Round One,
83% (131/159) of whom were on treatment for ≥25 weeks
and included in analyses. Refugees reported a median
time in the host country of 9.8 years (IQR 4.5, 15.7), and
median time since registration with UNHCR of 8.5 years
(IQR 2.8, 14.9). HIV-positive adults from the refugee
and host community had similar proportions of women
(67% vs 66%, p = 0.91) while having comparable median
durations on ART (147 vs 139 weeks, p = 0.65). Refugees
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were older than host nationals (median age 36 years vs
32 years, p = 0.02) (Table 1).
Round One
Virologic outcomes and adherence
Of all clients on treatment for ≥25 weeks, 50% (65/131)
had viral loads <5000 copies/mL. There was weak evi-
dence that a higher proportion of refugees were sup-
pressed at this level when compared with host nationals
(58% vs 43%; p = 0.10). There was strong evidence, how-
ever, that refugees had a lower median viral load at base-
line (3,830 copies/mL vs 7,905; p = 0.03) (Table 2). Mean
adherence to pharmacy refill schedule was 95.6%
(95%CI: 91.6, 99.6) for refugees, compared with 90.7%
(95%CI 91.6, 99.6) for host nationals (p = 0.11) (Additional
file 4). Comparing refugees and host nationals on adher-
ence measured by 4-day self-report (94.2% vs 92.2%, p =
0.62) and 1-month visual analogue scale (90.8% vs 87.3%,
p = 0.26) revealed only minor differences between groups.
Factors associated with virologic outcomes
Within the “treatment contexts level” (Additional file 1),
≥48 weeks between HIV diagnosis and ART start was as-
sociated with a fourfold increase in the odds of viral
suppression (AOR: 3.98, 95% CI 1.44, 11.01; p-trend =
0.006). The weak association between refugee status and
viral suppression in crude analyses (OR: 1.88, 95% CI
0.93, 3.81; p = 0.08) was further attenuated after adjust-
ing for age group, time on ART, time from HIV diagno-
sis to ART start, place of ART start, refill difficulties, and
food security (AOR: 0.51, 95% CI 0.08, 3.18; p = 0.46).
No evidence was found for associations with “self-
change factors” (Additional file 2). Among exposures in
the “action state” model, self-reported adherence to
medication schedule (AOR: 2.80, 95% CI 0.99, 7.90; p =
0.04) and self-reported dosing schedule (i.e., correct
reporting of dosing schedule) were associated with viral
suppression (AOR: 3.33, 95% CI 1.20, 9.24; p = 0.02)
(Additional file 3). There was also evidence that self-
reported adherence over the past month was associated
with decreased odds of viral suppression (AOR = 0.71,
95% CI 0.44, 1.14; p = 0.05). This association may have
been confounded by adjustment for refill difficulties in
the past three months. The magnitude of this confound-
ing was 58% (OR – AOR/AOR).
In the final multivariable model (Table 3), longer duration
between HIV diagnosis and ART start (≥48 weeks, AOR:
3.61, 95% CI 1.37, 9.47; p-trend = 0.01), self-reported
Fig. 1 Flow diagram of study participation. Legend: aReasons for loss to follow-up included (refugees): 18% (13/73) were active clients but not
found within the follow-up period; 12% (9/73) had missed ≥1 most recent pharmacy refills and were not found; 7% (5/73) of refugees were
resettled to a different country; 1% (1/73) had died; and 1% (1/73) had transferred to a different clinic. bReasons for loss to follow-up included
(host nationals): 19% (16/86) had missed ≥1 most recent pharmacy refills and were not found; 14% (12/86) were active clients but not found
within the follow-up period; 5% (4/86) had transferred to a different clinic; 4% (3/86) had died; and 1% (1/86) were approached but declined
Mendelsohn et al. Conflict and Health  (2017) 11:11 Page 4 of 11
Ta
b
le
1
So
ci
o-
de
m
og
ra
ph
ic
ch
ar
ac
te
ris
tic
s
of
re
fu
ge
es
an
d
ho
st
na
tio
na
ls
Fa
ct
or
Ro
un
d
O
ne
,a
ll
Ro
un
d
O
ne
,≥
25
w
ee
ks
on
tr
ea
tm
en
t
Ro
un
d
Tw
o
N
ot
in
cl
ud
ed
in
Ro
un
d
Tw
o
Re
fu
ge
e
(n
=
73
)
H
os
t
(n
=
86
)
p-
va
lu
e
Re
fu
ge
e
(n
=
59
)
H
os
t
(n
=
72
)
p-
va
lu
e
Re
fu
ge
e
(n
=
35
)
H
os
t
(n
=
43
)
p-
va
lu
e
Re
fu
ge
e
(n
=
29
)
H
os
t
(n
=
36
)
p-
va
lu
e
A
ge
,m
ed
ia
n
yr
s
(IQ
R)
36
(3
1,
41
)
32
(2
7,
38
)
0.
02
a
37
(3
3,
43
)
32
(2
7,
38
)
0.
00
1a
36
(3
3,
41
)
28
(2
4,
38
)
0.
02
a
39
(3
4,
43
)
31
(2
7,
39
)
0.
04
a
Fe
m
al
e
ge
nd
er
49
(6
7)
57
(6
6)
0.
91
38
(6
4)
48
(6
7)
0.
79
21
(6
0)
27
(6
3)
0.
80
17
(7
1)
2
(7
2)
0.
90
N
o
ea
rn
ed
in
co
m
ec
63
(8
6)
70
(8
1)
0.
41
49
(8
3)
57
(7
9)
0.
57
28
(8
0)
33
(7
8)
0.
73
21
(8
8)
24
(8
3)
0.
63
M
ar
rie
d/
co
ha
bi
tin
g
29
(4
0)
39
(4
5)
0.
48
23
(3
9)
32
(4
4)
0.
53
15
(4
3)
24
(5
6)
0.
26
8
(3
3)
8
(2
8)
0.
65
N
at
io
na
lit
y
Ke
ny
an
0
(0
)
86
(1
00
)
<
0.
00
1b
0
(0
)
72
(1
00
)
<
0.
00
1b
0
(0
)
43
(1
00
)
<
0.
00
1b
0
(0
)
29
(1
00
)
<
0.
00
1b
So
m
al
i,
Et
hi
op
ia
n,
Er
itr
ea
nd
36
(4
9)
0
(0
)
29
(4
9)
0
(0
)
14
(4
0)
0
(0
)
15
(6
3)
0
(0
)
Su
da
ne
se
20
(2
7)
0
(0
)
18
(3
1)
0
(0
)
14
(1
8)
0
(0
)
4
(1
7)
0
(0
)
Rw
an
de
se
,C
on
go
le
se
,B
ur
un
di
an
17
(2
3)
0
(0
)
12
(2
0)
0
(0
)
7
(2
0)
0
(0
)
5
(2
1)
0
(0
)
Tr
av
el
fo
r
≥
1
co
nt
in
uo
us
m
on
th
in
pa
st
ye
ar
8
(1
1)
22
(2
6)
0.
02
7
(1
2)
20
(2
8)
0.
03
3
(9
)
8
(1
9)
0.
21
4
(1
7)
12
(4
1)
0.
05
Se
lf-
re
po
rt
ed
co
ns
is
te
nt
ad
he
re
nc
e
to
m
ed
ic
at
io
n
sc
he
du
le
51
(7
1)
72
(8
4)
0.
05
44
(7
6)
60
(8
3)
0.
29
26
(7
4)
38
(8
8)
0.
11
18
(7
8)
22
(7
6)
0.
84
In
co
rr
ec
t
A
RT
do
si
ng
26
(3
6)
11
(1
3)
0.
00
1
20
(3
4)
8
(1
1)
0.
00
2
13
(3
7)
4
(9
)
0.
00
3
7
(2
9)
4
(1
4)
0.
17
Ti
m
e
on
A
RT
,m
ed
ia
n
w
ks
(IQ
R)
14
7
(3
8,
26
4)
13
9
(3
9,
22
5)
0.
65
a
20
2
(8
6,
27
0)
16
5
(9
6,
24
0)
0.
25
a
19
2
(8
0,
26
8)
19
0
(1
20
,2
35
)
0.
59
a
20
8
(8
7,
27
5)
12
0
(5
6,
24
2)
0.
29
a
Ti
m
e
fro
m
H
IV
di
ag
no
si
s
to
A
RT
,
m
ed
ia
n
w
ks
(IQ
R)
8
(0
,4
4)
15
(1
,5
6)
0.
26
a
4
(0
,2
3)
9
(0
,5
2)
0.
11
a
1
(0
,1
3)
9
(0
,5
6)
0.
04
a
10
(0
,6
7)
13
(1
,4
7)
0.
86
a
Ti
m
e
in
ho
st
co
un
tr
y,
m
ed
ia
n
w
ks
(IQ
R)
50
7
(2
34
,8
14
)
–
–
52
5
(2
65
,8
86
)
–
–
59
6
(3
09
,9
48
)
–
–
50
6
(2
34
,8
09
)
–
–
Va
lu
es
ar
e
nu
m
be
rs
(%
)
un
le
ss
ot
he
rw
is
e
st
at
ed
;p
-v
al
ue
s
ar
e
ch
i-s
qu
ar
e
te
st
s
un
le
ss
ot
he
rw
is
e
st
at
ed
;I
Q
R
in
te
rq
ua
rt
ile
ra
ng
e
a M
an
n-
W
hi
tn
ey
tw
o-
sa
m
pl
e
st
at
is
tic
(W
ilc
ox
on
ra
nk
-s
um
te
st
)
b
Fi
sh
er
’s
ex
ac
t
te
st
c N
ot
in
cl
ud
in
g
fin
an
ci
al
as
si
st
an
ce
pr
ov
id
ed
w
ith
in
re
fu
ge
e
ca
m
p
d
So
m
al
is
,E
th
io
pi
an
s,
an
d
Er
itr
ea
ns
w
er
e
gr
ou
pe
d
as
So
m
al
is
of
te
n
re
po
rt
ed
Et
hi
op
ia
n
na
tio
na
lit
y
to
co
nc
ea
li
de
nt
iti
es
Mendelsohn et al. Conflict and Health  (2017) 11:11 Page 5 of 11
adherence to medication schedule (AOR: 3.12, 95% CI 1.14,
8.49; p = 0.02), and self-reported dosing schedule (AOR:
2.52, 95% CI 0.96, 6.58; p = 0.05), were strongly associated
with viral suppression. There was no evidence for an associ-
ation between refugee status and viral suppression (AOR:
1.69, 95% CI 0.79, 3.57; p = 0.17). Age and time on ART
were not associated with the outcome in any models. All
effects in the final model were adjusted for age group, refu-
gee status, time on ART, and time from HIV diagnosis to
ART start.
Round Two
By the end of the Round Two follow-up period, 73%
(116/159) of all Round One participants had been
Table 3 Final multivariable model showing factors associated with viral suppression among refugees and host nationals on ART for
≥25 weeks at baseline in Kakuma, Kenya (N = 128a)
Factor Prevalence <5000 copies/mL, n/N (%) Crude odds ratio (95% CI) p-value Adjusted odds ratio (95% CI)b p-value
Age group (years)c
18+ 14/31 (45) 1 p(tr) = 0.90 1 p(tr) = 0.82
30+ 33/63 (52) 1.34 (0.56, 3.17) 1.47 (0.57, 3.76)
40+ 16/34 (47) 1.08 (0.41, 2.87) 0.90 (0.31, 2.59)
Refugee status
Host 9/20 (45) 1 p = 0.08 1 p = 0.17
Refugee 19/41 (46) 1.88 (0.93, 3.81) 1.69 (0.79, 3.57)
Time on ART (years)c 35/67 (52)
0- 1 p(tr) = 0.49 1 p(tr) = 0.76
1- 30/71 (42) 1.06 (0.36, 3.09) 0.80 (0.26, 2.49)
2+ 33/57 (58) 1.34 (0.49, 3.64) 1.00 (0.34, 2.95)
Time from HIV diagnosis to ART start (weeks)c
0- 8/29 (28) 1 p(tr) = 0.006 1 p(tr) = 0.01
24- 6/13 (46) 2.25 (0.58, 8.78) 2.71 (0.66, 11.11)
48+ 49/86 (57) 3.48 (1.39, 8.72) 3.61 (1.37, 9.47)
Adherence to medication schedule, self-reportedb
Inconsistent 7/25 (28) 1 p = 0.02 1 p = 0.02
Consistent 56/103 (54) 3.06 (1.18, 7.96) 3.12 (1.14, 8.49)
Self-reported dosing scheduleb, d
Incorrect dosing 11/28 (39) 1 p = 0.23 1 p = 0.05
Correct dosing 52/100 (52) 1.67 (0.71, 3.93) 2.52 (0.96, 6.58)
p-values are log likelihood ratio tests; CI, confidence interval
aThree clients with incomplete data were excluded
bAdjusted for all factors in table except adherence factors denoted by superscript d. Factors were not adjusted for adherence to avoid risk of over-adjustment bias
given that adherence mediates viral load
cFactor modelled as a linear effect; p(tr) = p(trend)
dIncorrect dosing was determined by comparing self-reported dosing schedules to standard dosing schedules [45]
Table 2 Comparison of HIV viral loads among refugees and host nationals taking ART for ≥25 weeks
Viral load Group Total, N (100%) <5000 copies/mL, n (%) p-value Median, copies/mL (IQR) p-value
Round One Refugee 59 34 (58) 0.10 3830 (1460, 14800) 0.03a
Kenyan 72 31 (43) 7905 (2625, 38900)
All 131 65 (50) 5010 (1920, 22400)
Round Two Refugee 35 26 (74) 0.66 1311 (<400, 6361) 0.41a
Kenyan 43 30 (70) 1411 (<400, 28107)
All 78 56 (72) 1368 (<400, 7477)
Differences in median viral load, baseline v. follow-up b: refugee, p = 0.04; Kenyan, p = 0.03; All, p = 0.002
p-values are chi-square tests unless otherwise stated; IQR interquartile range
aMann-Whitney two-sample statistic (Wilcoxon rank-sum test)
bWilcoxon signed-rank test
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engaged by a specialist adherence counselor and 3% (4/
159) were switched to second-line ART. Among clients
recruited in Round One, 60% (44/73) of refugees and
58% (50/86) of host nationals submitted a blood sample
in Round Two. There were no differences between those
with or without a follow-up viral load in relation to refu-
gee status (p = 0.96), age (p = 0.46) and gender (p = 0.23).
However, among the group participating in Round Two,
higher proportions were married (50% vs 30%, p = 0.02)
and had not travelled for ≥1 consecutive month in the
past year (30% vs 14%, p = 0.03) (Additional file 5).
Among refugees and host nationals who did not partici-
pate in Round Two, a greater proportion of the host
national group had travelled for ≥1 consecutive month
in the past year (Table 1). Among those who participated
in both rounds, median viral load declined between
rounds (5,010 copies/mL vs 1,368, p < 0.002). The fol-
low-up result was similar for refugees and host nationals
(1,311 copies/mL vs 1,411, p = 0.41). Among all who
tested <5000 copies/mL in Round One, 63% (24/38)
maintained viral suppression in Round Two (71%, 10/14
refugees; 58%, 14/24 host nationals). Proportions of refu-
gees and host nationals suppressed in Round Two were
similar (74% vs 70%, p = 0.66) (Table 2).
In samples submitted for drug resistance testing (n = 20;
8 refugees, 12 host nationals), 65% (13/20; 5 refugees, 8
host nationals) were successfully amplified. Of these, 69%
(9/13) exhibited drug resistant mutations (4/5 refugees,
5/8 host nationals). Resistance to two drug classes was
observed in 62% (8/13) of samples. The most prevalent
mutations were M184V (NRTI-associated mutation)
found in 54% (7/13) of samples and the K103N
(NNRTI-associated mutation) found in 46% (6/13) of
samples (Fig. 2). HIV-1 subtypes included sub-type A
(62%; 8/13), C (15%; 2/13), and D (23%; 3/13).
Discussion
In this study, the first of its kind to compare adherence
to ART and viral suppression among refugees and host
nationals who accessed ART from a refugee camp clinic,
we found unacceptably low proportions of viral suppres-
sion within both groups. Among those on treatment for
≥25 weeks in the Round One survey, only 50% had a
viral load of <5000 copies/mL. There was weak evidence
that refugees had attained a better viral response when
compared with host nationals in the Round One survey
(p = 0.10); however, in the final multivariable model refu-
gee status was not associated with viral suppression. Pro-
portions suppressed within each group were also similar
in Round Two.
Although improved in Round Two, proportions viro-
logically suppressed continued to be unacceptably low in
relation to other resource-limited settings [18–20].
Although virologic data from conflict-affected populations
are sparse, a South African study found that foreigners
had improved chances of viral suppression when com-
pared with locals [21]. In Kuala Lumpur, Malaysia, high
proportions of refugees and host nationals were virologic-
ally suppressed (81% v. 84%, p = 0.54) [6]. Strong out-
comes among refugees as measured by survival, CD4
counts and adherence were found in other conflict-
affected settings [22–24]. In the present study, the overall
proportion suppressed was lower in comparison to find-
ings from a meta-analysis of 89 studies of sub-Saharan Af-
rican HIV treatment programs that reported 67% viral
suppression after 12 months of ART [25].
In the present study, with the exception of host na-
tional self-reports over the past month, mean adherence
in Round One using any measurement was >85%. When
assessing these findings in relation to viral response and
leaving the possibility of drug resistance aside, it is
Fig. 2 Prevalence of drug resistant mutations (n = 20). Legend: NRTI = nucleoside reverse transcriptase inhibitor; NNRTI = non-nucleoside reverse
transcriptase inhibitor; PI = protease inhibitor. Mutations included M184V = 54% (7/13) of samples; K103N = 46% (6/13); K101E = 31% (4/13);
G190A =23% (3/13); P225H = 8%; Y181C = 8%, T215F = 8%; M46I = 8% (1/13)
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advisable that more sensitive measures of adherence be
used for monitoring purposes, especially where laboratory
monitoring is intermittent or unavailable. Notably, self-
reported dosing, which was defined as an incorrect self-
report of dosing schedule when compared with routine
dosing schedules, was associated with lack of viral sup-
pression. As ART tablets were distributed in small bags
with non-standardized, handwritten dosing instructions,
prescribed changes in the dosing or regimen may not have
been understood. Improvements in Round Two outcomes
suggested that basic program infrastructure, including
supportive services, may have been lacking.
The effect of longer duration between HIV diagnosis
and ART start on viral suppression (AOR: 3.98, 95% CI
1.44, 11.01; p-trend = 0.006) could have been related to
effective patient monitoring that enabled better pre-
paredness for ART when initiated in the home country
or in the refugee camp setting. A shorter duration be-
tween diagnosis and initiation may signal a lack of en-
gagement with health services. In other settings, delayed
ART initiation was shown to be a barrier to retention in
care [26, 27].
In drug resistance testing, 64% of successful amplifi-
cations exhibited resistance mutations. Assuming con-
servatively that the six unsuccessful amplifications
tested negative, 45% of samples would still have ex-
hibited major resistance mutations. This suggests that
drug resistance may be a serious problem within this
population. In 2011, eight years after ART roll-out in
East Africa, the estimated prevalence of drug resist-
ance among ART-naive individuals was 7.4% and
was increasing by 29% per year [28]. In two contrast-
ing Kenyan studies, the prevalence of transmitted re-
sistance between 2008 and 2010 was 1.1% in a rural
setting and 13.2% in an urban setting [29, 30]. Higher
levels of drug resistance in our study population
could have been linked to a history of treatment in-
terruptions before, during, or after displacement, but
prior to the self-reported recall period used to assess
adherence in our survey. This could help to explain
the discordance we detected between adherence and
viral suppression, whereby proportions suppressed
were much lower than what adherence levels would
suggest. Early-warning indicators for drug resistance
in African settings depend on prescribing practices,
patient retention, continuity of drug supply, and viral
suppression; therefore, effective patient monitoring is
critical when drug resistance testing is not routinely
available [31, 32].
Some important factors were not assessed in this
study. These included the effects of very high viral loads
at ART start, reduced potency of medications resulting
from hot storage conditions, and acute malnutrition.
Very high viral loads (≥100,000 copies/mL) are
associated with a lower likelihood of ever achieving viral
suppression [33]. Since viral load testing had not previ-
ously been implemented among this population, it was
not possible to evaluate this possibility. In Round One,
however, 15% (24/159) had a viral load in excess of
100,000 copies/mL. Although we did not measure acute
malnutrition quantitatively, in accompanying qualitative
work many clients reported that they were food insecure
and believed that ART was toxic when taken without suf-
ficient food [34]. Associations between food insecurity,
viral load and mortality have been reported in other popu-
lations [35, 36] and are thought to be mediated by drug
absorption and adherence [37–40]. Future studies con-
ducted in refugee settings should use a sensitive measure
of food insecurity to assess its true impact. Finally, we did
not test the potency of medications, therefore any impact
of storage conditions on potency could not be determined.
The average annual temperature in Kakuma is 28 °C and
can reach 40 °C or more in the dry season. The medica-
tions were stored in an indoor room that was not air
conditioned.
This study had several limitations. Adherence self-
reports may have suffered from recall and/or social
desirability biases. As the host national community were
primarily Turkana, a highly mobile group, findings may
not be generalizable to other Kenyan host nationals. Bias
may have been introduced to our comparisons of
refugees and host nationals if a local clinic at Kakuma
Mission Hospital had served healthier HIV-positive
Kenyans. We could not assess this bias as we did not
study this clinic. Risk factors were not assessed in Round
Two due to a lack of resources to implement a follow-up
survey questionnaire. Differences in mobility between
refugees and host nationals may have introduced bias if
one group had been less likely to participate in Round
Two [41, 42]. If this had resulted in a lower likelihood of
refilling prescriptions, for example, viral suppression
could have been overestimated in one group compared
with the other. The fact that few clients in Round Two
had travelled for at least one consecutive month in the
year prior to the study when compared with those who
participated only in Round One, suggested that the
Round Two cohort was more stable. Interestingly, the
Round Two cohort included a greater proportion of host
nationals who had travelled outside of the camp for one
month or more in the year prior to the study, yet fewer
were virologically suppressed in comparison to the refu-
gee group. Although the overall n was small, a notable
strength of the study was its relative completeness as
85% of all eligible clients were initially recruited. Strong
efforts were made to mitigate recall and social desirabil-
ity biases by conducting face-to-face interviews with
well-trained local researchers. As Kakuma was founded
in 1992, this setting was relatively stable and, arguably
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not generalizable to other acute humanitarian settings;
however, recent but periodic influxes of refugees due to
the intensification of conflicts in South Sudan and
Somalia suggest that this stability was unreliable. Given
that refugee settings around the world are often pro-
tracted, these findings might inform other, relatively
stable refugee camp settings.
Conclusions
In summary, unacceptably low proportions of refugees
and host nationals were virologically suppressed in
cross-sectional surveys conducted at two time-points. A
remedial intervention that strengthened clinic proce-
dures and adherence support between the surveys may
have helped to improve outcomes; however, this finding
was tentative given attrition between survey rounds. The
proportions suppressed at <5000 copies/mL in Round
Two were still unacceptably low, and drug resistance mu-
tations were found in a high proportion of those who were
not suppressed. Overall, there were only minor differences
between refugees and host nationals across outcome mea-
sures, suggesting that socio-structural factors operating at
the clinic level, not refugee status, were the best explan-
ation for observed levels of viral suppression. Future work
should evaluate interventions to improve adherence coun-
seling, monitoring, and viral suppression across the range
of settings where refugees and host nationals share HIV
services, including acute and longer-term humanitarian
settings and settings located outside of formal encamp-
ments. Within the framework of a public health approach
to ART focused on increasing levels of viral suppression by
retaining patients across the HIV cascade of care, these re-
sults have highlighted the importance of laboratory and
counseling services for vulnerable populations who ac-
cess services in remote settings. Given that early detec-
tion of treatment failures can prevent drug resistance
[43] and consistent viral suppression limits onward HIV
transmission [44], routine viral load testing using dried
blood spots and/or point of care devices should be
adopted in view of the potential long-term benefits. This
study serves as a clear reminder that programs operating
in remote settings should monitor performance carefully in
an effort to maintain consistently high levels of viral
suppression.
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